updated 4/14/2005 6:55:17 PM ET 2005-04-14T22:55:17

A federal judge on Thursday turned away the claims of generic drug manufacturers and ruled valid a patent for Eli Lilly & Co.’s best-selling drug, Zyprexa.

U.S. District Richard Young ruled in favor of Lilly on all of the matters in dispute in the case, Lilly said in a news release. However, appeals were likely.

Many Wall Street analysts had expected Lilly to prevail in the case and maintain exclusive U.S. rights to the treatment for schizophrenia and other disorders that brought in $4.42 billion for Lilly during 2004, or nearly a third of the Indianapolis-based company’s total revenues.

Three companies — Zenith Goldline Pharmaceuticals, owned by Ivax Corp. of Miami; Dr. Reddy’s Laboratories of India; and the U.S. arm of Israeli-based Teva Pharmaceutical Industries — challenged a 1993 patent that granted Lilly exclusive U.S. rights to the drug until 2011.

The three Lilly rivals argued during a three-week trial that concluded 14 months ago that the patent no longer was valid because discovery of the drug’s molecular structure was obvious and that a previous Lilly patent had covered it. The companies also claimed that Lilly misled the patent office and omitted certain test results when applying for the patent.

When Lilly lost the patent on the anti-depressant Prozac five years ago, it set off a slide in the company’s fortunes. Less expensive generic versions of the anti-depressant hit the market in late 2001 and soon captured most of Prozac’s market share.

© 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com